Unknown OBSERVATIONAL NCT05262660

The Long-term Effect of SAAE and Medical Treatment for Primary Aldosteronism

The Long-term Effect of Superselective Adrenal Arterial Embolization and Medical Treatment for Primary Aldosteronism on Cardiorenovascular Protection, Blood Pressure, and the Endocrinological Profile.

Sponsor: First Affiliated Hospital of Chengdu Medical College

Conditions Primary Aldosteronism

Updated 4 times since 2022 Last updated: Feb 21, 2022 Started: Apr 1, 2022 Primary completion: Jan 1, 2025 Completion: Jan 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Primary Aldosteronism and is currently ongoing. First Affiliated Hospital of Chengdu Medical College leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Feb 2025 — Present [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Apr 2022 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Chengdu Medical College

Data source: First Affiliated Hospital of Chengdu Medical College

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China